Search results
European pharma regulation changes signal tumult and transformation
Pharmaceutical Technology via Yahoo Finance· 3 hours agoThe two main tracks of regulation on everyone’s minds were the revised General Pharmaceutical...
Tapinarof may mark Dermavant’s first atopic dermatitis approval
Clinical Trials Arena via Yahoo Finance· 1 hour agoInnovator assets currently in pre-registration include Jiangsu Hengrui Medicine’s ivarmacitinib...
Veeva R&D Summit: Pharma companies need a say in AI regulation
Clinical Trials Arena via Yahoo Finance· 4 hours ago“As a result, it is important that everyone works together to at least share our views on this.” In...
Henan Lingrui Pharmaceutical Leads Three Key Dividend Stocks In China
Simply Wall St. via Yahoo Finance· 15 hours agoAs global markets grapple with mixed economic signals, China's equity landscape remains a focal...
Shares in Wegovy-maker Novo Nordisk climb, touching record high levels By Investing.com
Investing.com· 3 hours agoThe Danish pharmaceutical giant has seen its share price surge by more than 38% so far this year...
Insider Sale: EVP & CFO Charles F. Wagner Jr. Sells Shares of Vertex Pharmaceuticals Inc (VRTX) By...
Investing.com· 20 hours agoAccording to the SEC Filing, the transaction was executed at a stock price of $460, totaling...
Feel unveils a cutting-edge wearable device paired with AI for Emotional & Mental Health
PRWeb· 1 hour agoSAN FRANCISCO, June 6, 2024 /PRNewswire-PRWeb/ -- Feel Therapeutics, the Digital Precision Medicine...
GSK plc (NYSE:GSK) Stock Position Decreased by Peapack Gladstone Financial Corp
ETF DAILY NEWS· 5 hours agoThe institutional investor owned 23,173 shares of the pharmaceutical company’s stock after selling 1,441 shares during the quarter. Peapack Gladstone Financial Corp’s holdings ...
Aurinia reports improved lupus nephritis therapy outcomes By Investing.com
Investing.com· 20 hours agoROCKVILLE, Md. & EDMONTON, Alberta - Aurinia Pharmaceuticals Inc. (NASDAQ: NASDAQ:AUPH) shared...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives Buy Rating from Chardan Capital
ETF DAILY NEWS· 1 day agoArrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reiterated by Chardan Capital in a research note issued on Monday, Benzinga reports.